Escobar Carlos, Barrios Vivencio
Department of Cardiology, Hospital Infanta Sofia, Madrid, Spain.
Expert Rev Cardiovasc Ther. 2009 Mar;7(3):269-71. doi: 10.1586/14779072.7.3.269.
Evaluation of: Ostergren J, Poulter NR, Sever PS et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with Type II diabetes. J. Hypertens. 26, 2103-2111 (2008). Although blood pressure control is crucial to improve cardiovascular prognosis in patients with diabetes and hypertension, less than 10% of these patients attain blood pressure goals. European guidelines recommend that combined therapy should be used as first-line treatment in this population. The next step in the treatment of these patients is to determine which combination is preferable for each situation. The results of the Anglo-Scandinavian Cardiac Outcomes Trial demonstrated the benefits of amlodipine-based treatment on the incidence of total cardiovascular events and procedures, compared with atenolol-based treatment. In this article the potential explanations of these results are discussed.
奥斯特格伦 J、波尔特 NR、塞弗 PS 等。英-斯堪的纳维亚心脏结局试验：降压组：对 2 型糖尿病患者的影响。《高血压杂志》26 卷，2103 - 2111 页（2008 年）。尽管血压控制对于改善糖尿病和高血压患者的心血管预后至关重要，但这些患者中不到 10%能达到血压目标。欧洲指南建议联合治疗应作为该人群的一线治疗方法。治疗这些患者的下一步是确定哪种联合治疗在每种情况下更可取。英-斯堪的纳维亚心脏结局试验的结果表明，与以阿替洛尔为基础的治疗相比，以氨氯地平为基础的治疗对总心血管事件和手术发生率有好处。本文讨论了这些结果的潜在解释。
